Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 45Unknown 10Recruiting 7Active not recruiting 5Withdrawn 2Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 35Cyclophosphamide 30fludarabine phosphate 24fludarabine 24Rituximab 20Azacitidine 19Methotrexate 17venetoclax 16Peripheral Blood Stem Cell Transplantation 14Dasatinib 12Bendamustine Hydrochloride 12ibrutinib 11Filgrastim 11Busulfan 11Whole-Body Irradiation 10Granulocyte Colony-Stimulating Factor 10Tacrolimus 9Radiotherapy 9Lenalidomide 8Idarubicin 8Decitabine 8Vincristine 7Etoposide 7Dexamethasone 7Daunorubicin 7Cyclosporine 7merphos 6Prednisone 6Melphalan 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Thioguanine × Other hematologic neoplasm × Clear all
NCT06351306 2025-03-24

DEC-C and Thioguanine for R/R AML

Columbia University

Phase 2 Withdrawn
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT06210750 2024-05-17

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

National Cancer Institute (NCI)

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡